Scientific Publications

Asbach B et al.
Streamlining Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology. Feb 2016

Obuku AE et al.
Effect of Schistosoma mansoni infection on innate and HIV-1 specific T cell immune responses in HIV-1 infected Ugandan fisher folk. AIDS Res Hum Retroviruses. Feb 2016

García-Arriaza J et al.
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, Aug 2015

Shen X et al.
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology. Aug 2015

Bart PA et al.
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. Journal of Clinical Investigations. Nov 2014

Harari A, Rozot V, Cavassini M, Enders FB, Vigano S, Tapia G, Castro E, Burnet S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart P-A. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected ART-treated HIV patients. European Journal of Immunology. 2012

Quakkelaar ED et al.
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS ONE, Feb 2011

Kibler KV et al.
Improved NYVAC-based Vaccine Vectors. PLoS One. Nov 2011

Mooij P et al.
Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding HIV-1 clade C immunogens. Journal of Virology, 200

Bart P-A et al.
EV01: A phase 1 trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine, 2008

Corbett M et al.
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple and immunogenic.
Proceedings of the National Academy of Scienses. 2008

Harari A et al.
A HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. The Journal of Experimental Medicine, 2008

Gómez CE et al.
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Gene Therapy, 2008

McCormack S et al.
EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime –NYVAC-C boost to NYVAC-C alone. Vaccine, Jun 2008

Mooij P et al.
Differential CD4+ versus CD8+ responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
Journal of Virology, 2008

Vermeulen J et al.
TheraVac-02: An open-label phase I study to evaluate the safety of the HIV-1 vaccine MVA-B in chronic HIV-1 infected patients successfully treated with HAART. World AIDS Congress Mexico City, Mexico, 2008 (PDF)

Gómez CE et al.
Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. Journal of General Virology. 2007

Gómez CE et al.
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1 BX08 gp120 and HIV-1 IIIB Gag-Pol-Nef proteins of clade B. Vaccine. 2007 

Gómez CE et al.
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine. 2007

Guerra S et al. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kB-responsive genes in infected HeLa cells. Journal of Virology. 2006 

Nájera JL et al. 
Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of C7L gene. Journal of Virology. 2006